Jacobs Levy Equity Management Inc. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Jacobs Levy Equity Management Inc. decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 50.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 367,514 shares of the biotechnology company's stock after selling 372,085 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.18% of BioCryst Pharmaceuticals worth $2,793,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BCRX. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC boosted its holdings in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $63,000. Finally, DRW Securities LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $74,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of analyst reports. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded down $0.23 during trading hours on Friday, reaching $7.61. The company had a trading volume of 1,687,057 shares, compared to its average volume of 1,728,571. The business has a fifty day moving average price of $7.58 and a 200-day moving average price of $7.35. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The firm has a market cap of $1.58 billion, a PE ratio of -12.48 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The company's revenue for the quarter was up 35.1% on a year-over-year basis. During the same period last year, the firm posted ($0.19) EPS. Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.